Factsheets
 |
|
Photos
|
|
Bios
|
|
Dr. Norman Marcon, Gastroenterologist, St. Michael’s Hospital, Toronto
|
Dr. Marcon was appointed to the SAB in April 2000. He is a gastroenterologist and Past-Chief, Division of Gastroenterology of St. Michael’s Hospital, in Toronto, Ontario. He has been with St. Michael’s Hospital since 1972. Dr. Marcon is a Fellow, Royal College of Physicians and Surgeons of Canada and is a recipient of the Ontario Association of Gastroenterology Lifetime Achievement Award. He is also Associate Professor of Medicine, University of Toronto, in Toronto, Ontario.
|
Dennis Sprecher, MD, Director, Dyslipidemia Discovery Medicine, GlaxoSmithKline Pennsylvania
|
Dr. Sprecher was appointed to the SAB in April 1999. He is Director, Dyslipidemia Discovery Medicine at GlaxoSmithKline, in Pennsylvania. He was formerly the Section Head, Preventive Cardiology and Rehabilitation, The Cleveland Clinic Foundation. He is also Professor, Ohio State University, Department of Internal Medicine. Prior to joining The Cleveland Clinic in 1995, Dr. Sprecher was the Section Head of Preventative Cardiology at the University of Cincinnati, in Cincinnati, Ohio.
|
Michael Evelegh, PhD, Executive Vice President, Clinical and Regulatory Affairs, PreMD Inc.
|
Dr. Evelegh has 20 years of experience researching and developing human diagnostics, including product development, clinical trials, regulatory submissions and manufacturing. Dr. Evelegh leads PreMD’s scientific team at the company’s laboratory at McMaster University in Hamilton, Ontario. He is also chiefly responsible for evaluating the scientific potential of new technologies for PreMD’s pipeline.
Prior to joining PreMD, Dr. Evelegh directed research teams at other Canadian biotechnology companies, including Biomira Diagnostics Inc., and has been an independent scientific and regulatory consultant. He holds a PhD in immunology from McMaster University. |
Brent Norton, MD, MBA, President and CEO, PreMD Inc.
|
Dr. Norton founded PreMD in 1992 and has since served as President and Chief Executive Officer and as a Director. Active in medical practice, management and research for over 15 years, Dr. Norton has represented and led multiple medical groups and scientific initiatives. As a physician-entrepreneur, his cross-functional knowledge and skills enable him to guide PreMD and its products from the scientific stage through to successful commercialization.
Dr. Norton serves as a Director on the boards of public and private medical companies in Canada and the U.S. and is an Advisory Council Member of the Richard Ivey School of Business MBA Biotech Program. He is also an active volunteer, previously serving as Chairman, Friends Project, for the Canadian Institute for Advanced Research and as a committee member of a Canadian Intergovernmental Economic Commission, Advanced Technology Group.
Dr. Norton completed his medical training at McGill University in 1984. He subsequently completed a Master of Business Administration (1989) degree at the Richard Ivey School of Business, University of Western Ontario. |
